Minerva Neurosciences | NERV - Current Liabilities


Minerva Neurosciences reported $2.29M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Adma Biologics USD 75.76M 2.22M Jun/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
AstraZeneca USD 31.55B 1.02B Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Cipla INR 70.14B 7.16B Mar/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.04M 533K Mar/2026
CSL USD 4.61B 207M Dec/2025
Eli Lilly USD 47.74B 11.11B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Merck USD 27.73B 786M Jun/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Novavax USD 330.57M 11.89M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Takeda JPY 2.76T 335.02B Jun/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025